中生医疗(合肥)自2022年落户合肥经开区以来，依托区内优质创新资源加速成长，并在高端流式细胞仪 及配套试剂研发、市场推广等方面取得多项突破。该公司产品现已取得多项国家级及国际医疗器械认 证，业务覆盖全国31个省市自治区，并拓展至海外市场。 获颁本次荣誉，不仅有助于提升集团研发和技术创新品牌影响力，亦为集团进一步拓展大健康领域市场 奠定坚实基础。公司将继续大力支持旗下附属公司技术创新与产业化发展，积极扩展优质业务，提升竞 争力，为公司股东创造更大价值。 其中，中生医疗(合肥)自主研发的四光二十一色BioCyteX(临床)高端流式细胞仪已正式获证(皖械注准 20252220150)，是国内首款获得四光高端流式细胞仪注册证的国产品牌产品。该产品性能达国产顶配水 准，比肩国际进口品牌，亦宣告国产流式在尖端领域取得实质性突破，积极响应国家"国产替代"号召。 产品采用四个精密半导体激光器协同工作，可同步激发21种荧光染料并获取24项关键参数，其检测灵敏 度、分辨率与稳定性均达到国际领先水平，满足临床高复杂度免疫分型、微小残留病(MRD) 监测等核 心需求。此次BioCyteX 流式细胞仪的成功获批，标志着国产流式在复杂 ...

Core Viewpoint - Tianjin Atongmu Robot Co., Ltd. has officially submitted its prospectus to the Hong Kong Stock Exchange, marking its entry into the capital market as a leading player in the parallel robot sector [1][4]. Company Overview - Atongmu Robot has maintained the largest market share among domestic brands in China's parallel robot market for five consecutive years since 2020 [4]. - In 2024, Atongmu Robot ranked second globally in the parallel robot market with a 4.8% market share, only behind ABB, showcasing its strong technical capabilities and market position [4]. - The company was established in January 2013 as Chensheng (Tianjin) Automation Equipment Co., Ltd. and transitioned to a joint-stock company in September 2025, changing its name to Tianjin Atongmu Robot Co., Ltd. [4]. Technological Development - The company leverages cutting-edge research resources from Tianjin University and Beihang University, focusing on the development of parallel robots, high-speed SCARA robots, collaborative robots, embodied intelligent robots, and key control systems [5]. - Atongmu Robot's products cater to automation and intelligence needs in various industries, including food and beverage, daily chemicals, pharmaceuticals, new energy, 3C, and automotive sectors [5]. - In June 2025, the company launched Tianjin's first embodied intelligent robot, "Tianbing No. 1 ATOM01," indicating its commitment to innovation and industry upgrades [5]. Market Insights - According to Frost & Sullivan, China's industrial robot market is projected to grow from CNY 31.4 billion in 2020 to CNY 46.6 billion in 2024, with a compound annual growth rate (CAGR) of 10.3% [6]. - The global parallel robot market is expected to reach CNY 7.8 billion by 2029, with the Chinese market accounting for approximately CNY 1.9 billion [6]. - The high technical barriers in the parallel robot sector provide established companies like Atongmu Robot with competitive advantages, especially during the domestic substitution phase in China's manufacturing industry [6].

Core Viewpoint - The recent share reduction actions by the National Integrated Circuit Industry Investment Fund (referred to as "National Big Fund") in the semiconductor sector are viewed as normal investment exit behaviors, and the strategic direction of supporting domestic substitution remains unchanged [1][7]. Group 1: Share Reduction Activities - The National Big Fund plans to reduce its holdings in Anlu Technology (688107.SH) by up to 2% of the total share capital within three months, marking the third reduction since 2025 [1][2]. - Other semiconductor companies, including Hu Silicon Industry (688126.SH) and Tailin Micro (688591.SH), have also disclosed recent share reduction plans by the National Big Fund [1][2]. - As of the announcement date, the National Big Fund held 22.95 million shares of Anlu Technology, accounting for 5.73% of the total share capital, with a planned reduction estimated at approximately 226 million yuan [2][3]. Group 2: Financial Performance and Market Reaction - Hu Silicon Industry's stock price has underperformed, with a cumulative increase of only 14.98% in 2025, compared to a 44% increase in the semiconductor chip index, indicating a lag of nearly 30 percentage points [4]. - The company is expected to report a significant loss of 1.28 billion to 1.53 billion yuan for 2025, with a projected loss of 1.5 billion to 1.8 billion yuan after excluding non-recurring items [4][5]. - The decline in performance is attributed to structural differentiation in semiconductor demand, underperformance of acquired subsidiaries, and ongoing capacity expansion projects [5]. Group 3: Market Analysis and Future Outlook - Market analysts believe that the National Big Fund's reduction actions are part of a market-oriented and routine operation strategy, facilitating a positive cycle of "investment-exit-reinvestment" [7]. - The National Big Fund's first phase, established in 2014, is entering the latter half of its investment recovery period, while the larger second and third phases will focus on supporting critical areas in the semiconductor supply chain [7].

Core Viewpoint - The National Integrated Circuit Industry Investment Fund (referred to as "National Big Fund") has been actively reducing its holdings in the semiconductor sector since the beginning of the year, which has drawn significant market attention [1] Group 1: Fund Reduction Activities - On February 8, Anlu Technology (688107.SH) announced that the Big Fund Phase I plans to reduce its holdings by no more than 2% of the company's total share capital within the next three months [1] - This marks the third time since 2025 that Anlu Technology has faced a reduction plan from the Big Fund [1] - Other semiconductor companies such as Hu Silicon Industry (688126.SH), Tailin Micro (688591.SH), and Huizhi Micro (688512.SH) have also recently disclosed the latest reduction progress or plans from the Big Fund [1] Group 2: Long-term Strategy - Despite the frequent short-term reduction activities, the industry generally views this as a normal exit behavior for an investment fund, indicating that the strategic direction of supporting domestic growth and facilitating domestic substitution remains unchanged [1]

Core Viewpoint - The National Integrated Circuit Industry Investment Fund (referred to as "National Big Fund") has been actively reducing its holdings in semiconductor companies, which has drawn market attention. This is seen as a normal investment exit behavior rather than a shift in the long-term strategy to support domestic industry growth and replacement [1][7]. Group 1: National Big Fund's Reduction Actions - The National Big Fund plans to reduce its stake in Anlu Technology (688107.SH) by up to 2% of the total share capital within three months, marking the third reduction since 2025 [1][2]. - Other semiconductor companies such as Hu Silicon Industry (688126.SH) and Tailin Micro (688591.SH) have also disclosed similar reduction plans, indicating a broader trend across the sector [1][2]. - The first phase of the National Big Fund holds 22.95 million shares of Anlu Technology, representing 5.73% of the total share capital, with a planned reduction of approximately 8.017 million shares, estimated to be worth around 226 million yuan [2][3]. Group 2: Performance and Financials of Hu Silicon Industry - Hu Silicon Industry's stock price has been underperforming, with a cumulative increase of only 14.98% in 2025, significantly lagging behind the semiconductor chip index's 44% increase [4]. - The company is expected to report a net loss of 1.28 billion to 1.53 billion yuan for 2025, with a projected loss of 1.5 billion to 1.8 billion yuan after excluding non-recurring items, indicating a worsening financial situation [4][5]. - The decline in performance is attributed to structural changes in semiconductor demand, underperformance of acquired subsidiaries, and ongoing capacity expansion projects [5]. Group 3: Market Implications and Future Outlook - Analysts view the National Big Fund's reduction actions as part of a market-oriented and routine operation strategy, which facilitates a healthy cycle of investment, exit, and reinvestment [7]. - The first phase of the National Big Fund is entering the latter half of its investment recovery period, while the larger second and third phases will focus on supporting critical areas in the semiconductor supply chain [7].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任 何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 自願公告 合肥附屬公司榮獲2025年度「科創新星企業」稱號 本公告乃由中生北控生物科技股份有限公司（「本公司」，與其附屬公司統稱為「本 集團」）自願作出，旨在向本公司股東及投資者提供最新資訊。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於2026年2月4日舉行的合肥經濟技 術開發區2026年企業新春團拜會上，本公司間接非全資附屬公司－中生醫療科技（合 肥）有限公司（「中生醫療（合肥）」）憑藉其於體外診斷領域的創新實力及穩健發展 潛力，被授予「2025年度合肥經濟技術開發區科創新星企業」榮譽稱號。該榮譽由 合肥經開區黨工委及管委會授出，是對中生醫療（合肥）過往科技創新成果的權威 肯定，亦彰顯其未來發展潛力。 其中，中生醫療（合肥）自主研發的四光二十一色BioCyteX（臨床）高端流式細胞 儀已正式獲證（皖械注准20252220150)，是國內首款獲得四光高端流式細胞儀註冊 證的國產品牌產品。該產品性 ...

Core Viewpoint - The company is focusing on enhancing its product series and expanding into new application areas by collaborating with research institutions and responding to market demands [1] Group 1 - The company aims to achieve breakthroughs in fields such as life sciences, semiconductors, rare and precious metal separation and extraction, and nuclear-grade resins [1] - The company emphasizes its commitment to comply with relevant laws and regulations regarding information disclosure [1] - The company will announce any significant matters that meet disclosure standards in a timely manner [1]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1][9]. Core Insights - The company has shown steady revenue growth, with a reported revenue of 233 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 3.48%. However, net profit attributable to shareholders decreased by 4.79% to 14 million yuan due to short-term impacts from share-based payments [4]. - The company focuses on independent innovation, with its products filling domestic technological gaps. Key technology indicators of its products are at a leading domestic and advanced international level, showcasing strong potential for domestic substitution [5]. - The company is expanding its market presence through collaborations with leading international and domestic firms, enhancing its core competitive barriers. Notable products like the QT-8400 series have made significant technological breakthroughs and are entering important customer supply chains [6]. - The company is accelerating the development of high-performance SoC testing machines, capitalizing on the growing demand for domestic alternatives in the high-end SoC testing market [7]. Financial Projections - Revenue projections for the company are estimated at 360 million yuan in 2025, 600 million yuan in 2026, and 1 billion yuan in 2027, with corresponding net profits of 36 million yuan, 122 million yuan, and 246 million yuan respectively [8][11]. - The company is expected to achieve a significant growth rate of 66.94% in 2026 and 65.46% in 2027 [11]. - The earnings per share (EPS) is projected to increase from 0.51 yuan in 2025 to 3.49 yuan in 2027 [11]. Relative Valuation - The company is positioned in the semiconductor backend testing equipment sector, with a focus on automated testing systems and laser marking equipment. It has successfully achieved import substitution in power semiconductor testing systems and is among the few Chinese semiconductor equipment companies to penetrate the international testing market [14]. - The report references a relative valuation analysis with a projected price-to-sales (P/S) ratio of 23.04x for 2025, supporting the "Buy" rating [14][15].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [5][10]. Core Insights - The company is strategically investing in core assets, which may lead to temporary profit pressure. It is projected to incur a net loss attributable to shareholders of between -12 million to -6 million yuan in 2025, primarily due to increased investments in key resources, advanced capacity, and talent reserves [3][5]. - The company has successfully completed its domestic and international capacity layout in Shenyang, Nantong, Beijing, and Singapore, significantly increasing its fixed asset scale to approximately 4.9 billion yuan, a growth of about 3.5 billion yuan compared to 2022 [4]. - The company is focusing on advanced process development, with new projects such as gas distribution plates and special coatings already validated and in mass production [4][10]. - The company is expected to achieve revenues of 3.75 billion, 5 billion, and 7 billion yuan in 2025, 2026, and 2027 respectively, with a projected net profit of -0.08 billion, 0.3 billion, and 0.66 billion yuan for the same years [5][9]. Financial Projections - Revenue is projected to grow at rates of 47.14%, 23.48%, 33.49%, and 39.80% for the years 2024, 2025, 2026, and 2027 respectively [9][12]. - The company’s EBITDA is expected to increase from 507.87 million yuan in 2024 to 1.41 billion yuan in 2027 [9]. - The net profit attributable to shareholders is forecasted to recover from a loss of 7.9 million yuan in 2025 to a profit of 660.43 million yuan in 2027, reflecting a significant turnaround [9][12].

Investment Rating - The report assigns a "Buy-B" rating to the company, indicating a positive outlook for its stock performance in the near term [10]. Core Insights - The company is expected to achieve revenue growth from 7.19 billion to 14.17 billion yuan from 2025 to 2027, with a significant increase in net profit projected during the same period [8][12]. - The company is actively expanding its production capacity through a private placement, raising up to 671 million yuan for projects including intelligent manufacturing upgrades and the development of low-dielectric loss flexible copper-clad laminates (FCCL) [4][6]. - The company has seen robust revenue growth of 42.04% year-on-year in the first three quarters of 2025, with net profit increasing by 36.17% [5]. Financial Performance - For the first three quarters of 2025, the company reported revenues of 500 million yuan and a net profit of 91 million yuan, with quarterly revenues showing consistent growth [5]. - The company's earnings per share (EPS) are projected to rise from 1.64 yuan in 2025 to 3.43 yuan by 2027, reflecting strong profitability [12][14]. - The return on equity (ROE) is expected to improve from 17.2% in 2025 to 22.6% in 2027, indicating enhanced efficiency in generating profits from shareholders' equity [12]. Market Position and Strategy - The company is increasing its stake in Lingtianda to 51%, enhancing its position in the wire and cable sector, which is expected to become a significant growth driver [7]. - The demand for the company's products, particularly in the automotive sector, is anticipated to grow rapidly due to trends in electrification and smart technology [6]. - The company aims to break the foreign monopoly in high-end FCCL materials, which are currently dominated by companies like DuPont and Panasonic, thereby enhancing its competitive edge [6].